

Attorney Docket No. P33037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Damiani et al. December 7, 2007
Appln. No.: 10/511,769 Group Art Unit No.: 1625
Filed: May 2, 2005 Examiner: C. C. Chang
For: COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE
THEREOF IN THERAPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

This paper is in response to the Restriction Requirement mailed November 7, 2007, having a shortened statutory period for reply of 1 month.

Claims 1-21 are pending in the application. Claims 20-21 are withdrawn from consideration. Claims 1-19 are subject to a restriction requirement and/or election requirement.

Restriction to one of the following was required under 35 U.S.C. §121 and 372:

Group I. Claims 2 and 4 in their entirety, 1, 3, 5-17 in part when X1 is CHR5, drawn to compounds with 2-oxo-pyrrolidinyl core, process of making and composition thereof. If this group is elected, a further election of a single disclosed species is also required.

- Group II. Claims 1, 3, 5-17 when X1 is a two carbon linker (CH₂CH₂, CH=CH, C(CH₃)₂), drawn to compounds with a 2-oxo-pyridinyl/piperidinyl core, process of making and composition thereof. If this group is elected, a further election of a single disclosed species is also required.
- Group III. Claims 1, 3, 5-10, 12-17, when X1 is a three carbon linker, drawn to compounds with a 2-oxo-azepidinyl core, process of making and composition thereof. If this group is elected, a further election of a single disclosed species is also required.
- Group IV. Claims 18-19, drawn to a method of treating CNS disorder. If this group is elected, a further election of a single disclosed disorder and a single disclosed compound for treating the elected disorder is also required.